68 related articles for article (PubMed ID: 24402943)
21. Differential effects of HIF2α antagonist and HIF2α silencing in renal cancer and sensitivity to repurposed drugs.
Arnaiz E; Miar A; Bridges E; Prasad N; Hatch SB; Ebner D; Lawrie CH; Harris AL
BMC Cancer; 2021 Aug; 21(1):896. PubMed ID: 34353313
[TBL] [Abstract][Full Text] [Related]
22. HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans.
Ma Y; Joyce A; Brandenburg O; Saatchi F; Stevens C; Toffessi Tcheuyap V; Christie A; Do QN; Fatunde O; Macchiaroli A; Wong SC; Woolford L; Yousuf Q; Miyata J; Carrillo D; Onabolu O; McKenzie T; Mishra A; Hardy T; He W; Li D; Ivanishev A; Zhang Q; Pedrosa I; Kapur P; Schluep T; Kanner SB; Hamilton J; Brugarolas J
Clin Cancer Res; 2022 Dec; 28(24):5405-5418. PubMed ID: 36190432
[TBL] [Abstract][Full Text] [Related]
23. hsa-mir-30c promotes the invasive phenotype of metastatic breast cancer cells by targeting NOV/CCN3.
Dobson JR; Taipaleenmäki H; Hu YJ; Hong D; van Wijnen AJ; Stein JL; Stein GS; Lian JB; Pratap J
Cancer Cell Int; 2014; 14():73. PubMed ID: 25120384
[TBL] [Abstract][Full Text] [Related]
24. MiR-30a-3p negatively regulates BAFF synthesis in systemic sclerosis and rheumatoid arthritis fibroblasts.
Alsaleh G; François A; Philippe L; Gong YZ; Bahram S; Cetin S; Pfeffer S; Gottenberg JE; Wachsmann D; Georgel P; Sibilia J
PLoS One; 2014; 9(10):e111266. PubMed ID: 25360821
[TBL] [Abstract][Full Text] [Related]
25. Hif-1α and Hif-2α differentially regulate Notch signaling through competitive interaction with the intracellular domain of Notch receptors in glioma stem cells.
Hu YY; Fu LA; Li SZ; Chen Y; Li JC; Han J; Liang L; Li L; Ji CC; Zheng MH; Han H
Cancer Lett; 2014 Jul; 349(1):67-76. PubMed ID: 24705306
[TBL] [Abstract][Full Text] [Related]
26. Integrative Transcriptomic Profiling of the Wilms Tumor.
Avčin SL; Črepinšek K; Jenko Bizjan B; Šket R; Kovač J; Vrhovšek B; Blazina J; Blatnik O; Kordič R; Kitanovski L; Jazbec J; Debeljak M; Tesovnik T
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568662
[TBL] [Abstract][Full Text] [Related]
27. Tumor-Suppressive and Immunomodulating Activity of miR-30a-3p and miR-30e-3p in HNSCC Cells and Tumoroids.
Conrad O; Burgy M; Foppolo S; Jehl A; Thiéry A; Guihard S; Vauchelles R; Jung AC; Mourtada J; Macabre C; Ledrappier S; Chenard MP; Onea MA; Danic A; Dourlhes T; Thibault C; Schultz P; Dontenwill M; Martin S
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446353
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic modification of BDNF mediates neuropathic pain via miR-30a-3p/EP300 axis in CCI rats.
Tan M; Shen L; Hou Y
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33103739
[TBL] [Abstract][Full Text] [Related]
29. The tumor microenvironment in renal cell cancer.
Mier JW
Curr Opin Oncol; 2019 May; 31(3):194-199. PubMed ID: 30985497
[TBL] [Abstract][Full Text] [Related]
30. From conventional therapy toward microRNA-based therapy in acute promyelocytic leukemia.
Ehtesham N; Sharifi M
Adv Biomed Res; 2016; 5():187. PubMed ID: 28028527
[TBL] [Abstract][Full Text] [Related]
31. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
[TBL] [Abstract][Full Text] [Related]
32. MicroRNAs in Cancer Biology and Therapy: Current Status and Perspectives.
Price C; Chen J
Genes Dis; 2014 Sep; 1(1):53-63. PubMed ID: 25473652
[TBL] [Abstract][Full Text] [Related]
33. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
[TBL] [Abstract][Full Text] [Related]
34. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
[TBL] [Abstract][Full Text] [Related]
35. [Tumor suppressor gene VHL, hypoxia inducible factor, and renal cell carcinoma].
Zhang YT; Chen N; Zeng H; Zhou Q
Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):562-4. PubMed ID: 17134554
[No Abstract] [Full Text] [Related]
36. Metabolism of kidney cancer: from the lab to clinical practice.
Sudarshan S; Karam JA; Brugarolas J; Thompson RH; Uzzo R; Rini B; Margulis V; Patard JJ; Escudier B; Linehan WM
Eur Urol; 2013 Feb; 63(2):244-51. PubMed ID: 23063455
[TBL] [Abstract][Full Text] [Related]
37. miR-30c-2-3p and miR-30a-3p: new pieces of the jigsaw puzzle in HIF2α regulation.
Moch H; Lukamowicz-Rajska M
Cancer Discov; 2014 Jan; 4(1):22-4. PubMed ID: 24402943
[TBL] [Abstract][Full Text] [Related]
38. Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity.
Mathew LK; Lee SS; Skuli N; Rao S; Keith B; Nathanson KL; Lal P; Simon MC
Cancer Discov; 2014 Jan; 4(1):53-60. PubMed ID: 24189146
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
